title: Tuberculosis in hematopoietic stem cell transplant recipients.
abstract: Literature on tuberculosis (TB) occurring in recipients of Hematopoietic Stem Cell Transplant (HSCT) is scanty even in countries where TB is common. Most reports of TB in HSCT patients were from ASIA, in fact the TB incidence ranging from 0.0014 (USA) to 16% (Pakistan). There are few reports of TB diagnosis during the first two weeks after HSCT; most of cases described in the literature occurred after 90 days of HSCT, and the lung was the organ most involved. The mortality ranged from 0 to 50% and is higher in allogeneic HSCT than in autologous. There is no consensus regarding the screening with tuberculin skin test or QuantiFERON-TB gold, primary prophylaxis for latent TB, and whether the epidemiologic query should be emphasized in developing countries with high prevalence of TB.
authors.affiliation: Group of Infection in immunocompromised patients of Hospital das Clinicas of University of São Paulo, Brazil.
authors.forename: Jéssica Fernandes
authors.initials: JF
authors.lastname: Ramos
authors.affiliation: Group of Infection in immunocompromised patients of Hospital das Clinicas of University of São Paulo, Brazil.
authors.forename: Marjorie Vieira
authors.initials: MV
authors.lastname: Batista
authors.affiliation: Group of Infection in immunocompromised patients of Hospital das Clinicas of University of São Paulo, Brazil. ; Department of Infectious Diseases, Medical School, University of São Paulo, São Paulo, Brazil.
authors.forename: Silvia Figueiredo
authors.initials: SF
authors.lastname: Costa